WUHAN, China, Sept. 10, 2018 /PRNewswire/ -- XW Laboratories Inc. (XW Labs), a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics for the treatment of neurological disorders, today announced the appointment of Daniel M. Canafax, PharmD as Chief Medical Officer. Dr. Canafax will lead the global clinical development of XW10172, XW Labs' novel therapy for treating narcolepsy, and the company's expanding pipeline of small molecule therapies expected to enter clinical development over the next few years.

"Our global pipeline is rapidly entering into early and later stage clinical development", said Dr. Jia-Ning Xiang, Founder and Chief Executive Officer of XW Labs. "We are pleased to have Dr. Canafax join our senior leadership team to lead these efforts. His wealth of R&D knowledge and strong track record for clinical development execution will bridge our novel drug discovery research to therapies that help patients with unmet medical needs."